Assessing bleeding risk in patients taking anticoagulants

Abstract

Anticoagulant medications are commonly used for the prevention and treatment of thromboembolism. Although highly effective, they are also associated with significant bleeding risks. Numerous individual clinical factors have been linked to an increased risk of hemorrhage, including older age, anemia, and renal disease. To help quantify hemorrhage risk for individual patients, a number of clinical risk prediction tools have been developed. These risk prediction tools differ in how they were derived and how they identify and weight individual risk factors. At present, their ability to effective predict anticoagulant-associated hemorrhage remains modest. Use of risk prediction tools to estimate bleeding in clinical practice is most influential when applied to patients at the lower spectrum of thromboembolic risk, when the risk of hemorrhage will more strongly affect clinical decisions about anticoagulation. Using risk tools may also help counsel and inform patients about their potential risk for hemorrhage while on anticoagulants, and can identify patients who might benefit from more careful management of anticoagulation.

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

“…The introduction of oral direct inhibitors of factor Xa or thrombin has greatly improved medical care and safety in the prevention and treatment of thrombotic disorders. However, bleeding remains a concern, particularly in patients with risk factors such as advancing age, anemia, and renal disease . As such, there remains a medical need for new agents with an improved safety profile and equivalent or superior efficacy compared with existing therapies …”

Effects of therapeutic plasma exchange on anticoagulants in patients receiving therapeutic anticoagulation: a systematic review

“…TPE's hemostatic effects are likely to be amplified by the addition of therapeutic anticoagulation. Due to their known effects on coagulation proteins, therapeutic anticoagulants increase bleeding risk . However, studies suggest that, depending on the pharmacokinetic profile and timing of administration relative to the TPE procedure, anticoagulants are removed by TPE .…”

Guideline‐concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D

“…Nevertheless, evidence shows that providers often overestimate the risk of intracranial hemorrhage among AF patients . In one observational study among Medicare beneficiaries with AF at high risk of falls, ischemic stroke was nearly five times more common than intracranial hemorrhage . Increasing provider education on incidence of intracranial hemorrhage during OAC therapy is therefore likely to increase initiation of these drugs in AF patients.…”